We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
Read MoreHide Full Article
Pfizer (PFE - Free Report) announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved.
Why PFE is Withdrawing the Drug All of a Sudden?
This decision is based on the totality of clinical data, which shows that the benefit of the drug no longer outweighs the risks associated with its use. Per management, the data reflected an imbalance in vaso-occlusive crises (a common and painful complication of SCD) and fatal events that required further assessment.
Pfizer also notified regulatory authorities of these findings and its decision to withdraw the drug from the market. The company also decided to discontinue all clinical studies and access programs related to Oxbryta.
This withdrawal decision comes a couple of months after the EMA started a review of the drug. The agency initiated this review after data from two clinical studies evaluating Oxbryta showed a higher-than-expected number of deaths.
Oxbryta was added to Pfizer’s portfolio following its acquisition of Global Blood Therapeutics in 2022 for nearly $5.4 billion. The drug was initially approved by the FDA in 2019 under the accelerated pathway for use in SCD patients aged 12 years and older. The agency subsequently converted this nod to full approval in 2021 and expanded its use in patients as young as four years. The SCD drug is currently approved in more than 35 countries for SCD, including Europe.
PFE Stock Performance
Year to date, Pfizer’s shares have risen 0.4% compared with the industry’s 22.5% rise.
Image Source: Zacks Investment Research
Financial Impact of Oxbryta Withdrawal on Pfizer
Per management, the drug’s withdrawal is not expected to impact its financial guidance for 2024. Sales of the medication have been modest compared with other drugs in Pfizer’s portfolio. During the first half of 2024, Pfizer generated $176 million from Oxbryta sales, up 19% year over year.
Management previously raised its guidance for the year when it reported second-quarter 2024 results in July. Pfizer expects total revenues in the range of $59.5-$62.5 billion versus the prior expectation of $58.5-$61.5 billion.
Adjusted earnings are expected in the range of $2.45-$2.65 versus the prior expectation of $2.15-$2.35 per share. This range includes the expected impact of 40 cents dilution from the Seagen acquisition mainly due to the costs of financing the transaction.
In the past 60 days, estimates for Bioventus’ 2024 earnings per share (EPS) have risen from 27 cents to 40 cents. Estimates for 2025 have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 120.5%.
BVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.
In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have risen from $2.09 to $2.38. Estimates for 2025 have increased from $4.33 to $7.31 during the same period. Year to date, Krystal Biotech’s shares have surged 44.7%.
Earnings of Krystal Biotech beat estimates in three of the last four quarters and missed the mark on one occasion. Krystal Biotech delivered a four-quarter average earnings surprise of 45.95%.
In the past 60 days, estimates for ADMA Biologics’ 2024 EPS have risen from 35 cents to 49 cents. EPS Estimates for 2025 have increased from 53 cents to 64 cents during the same period. Year to date, shares of ADMA Biologics have skyrocketed 331.2%.
ADMA’s earnings beat estimates in each of the last four quarters. ADMA Biologics delivered a four-quarter average earnings surprise of 105.63%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
Pfizer (PFE - Free Report) announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved.
Why PFE is Withdrawing the Drug All of a Sudden?
This decision is based on the totality of clinical data, which shows that the benefit of the drug no longer outweighs the risks associated with its use. Per management, the data reflected an imbalance in vaso-occlusive crises (a common and painful complication of SCD) and fatal events that required further assessment.
Pfizer also notified regulatory authorities of these findings and its decision to withdraw the drug from the market. The company also decided to discontinue all clinical studies and access programs related to Oxbryta.
This withdrawal decision comes a couple of months after the EMA started a review of the drug. The agency initiated this review after data from two clinical studies evaluating Oxbryta showed a higher-than-expected number of deaths.
Oxbryta was added to Pfizer’s portfolio following its acquisition of Global Blood Therapeutics in 2022 for nearly $5.4 billion. The drug was initially approved by the FDA in 2019 under the accelerated pathway for use in SCD patients aged 12 years and older. The agency subsequently converted this nod to full approval in 2021 and expanded its use in patients as young as four years. The SCD drug is currently approved in more than 35 countries for SCD, including Europe.
PFE Stock Performance
Year to date, Pfizer’s shares have risen 0.4% compared with the industry’s 22.5% rise.
Image Source: Zacks Investment Research
Financial Impact of Oxbryta Withdrawal on Pfizer
Per management, the drug’s withdrawal is not expected to impact its financial guidance for 2024. Sales of the medication have been modest compared with other drugs in Pfizer’s portfolio. During the first half of 2024, Pfizer generated $176 million from Oxbryta sales, up 19% year over year.
Management previously raised its guidance for the year when it reported second-quarter 2024 results in July. Pfizer expects total revenues in the range of $59.5-$62.5 billion versus the prior expectation of $58.5-$61.5 billion.
Adjusted earnings are expected in the range of $2.45-$2.65 versus the prior expectation of $2.15-$2.35 per share. This range includes the expected impact of 40 cents dilution from the Seagen acquisition mainly due to the costs of financing the transaction.
PFE Zacks Rank
Pfizer currently carries a Zacks Rank #2 (Buy).
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Our Key Picks Among Biotech Stocks
Some other top-ranked stocks include ADMA Biologics (ADMA - Free Report) , Bioventus (BVS - Free Report) and Krystal Biotech (KRYS - Free Report) . While BVS and KRYS each sport a Zacks Rank #1 (Strong Buy), ADMA carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Bioventus’ 2024 earnings per share (EPS) have risen from 27 cents to 40 cents. Estimates for 2025 have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 120.5%.
BVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.
In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have risen from $2.09 to $2.38. Estimates for 2025 have increased from $4.33 to $7.31 during the same period. Year to date, Krystal Biotech’s shares have surged 44.7%.
Earnings of Krystal Biotech beat estimates in three of the last four quarters and missed the mark on one occasion. Krystal Biotech delivered a four-quarter average earnings surprise of 45.95%.
In the past 60 days, estimates for ADMA Biologics’ 2024 EPS have risen from 35 cents to 49 cents. EPS Estimates for 2025 have increased from 53 cents to 64 cents during the same period. Year to date, shares of ADMA Biologics have skyrocketed 331.2%.
ADMA’s earnings beat estimates in each of the last four quarters. ADMA Biologics delivered a four-quarter average earnings surprise of 105.63%.